Stock Analiz

Healthstream Inc. HSTM

Computer Software: Programming Data Processing · IPO 2000 · data as of November 13, 2026

$27.97Market cap $857M
Open the interactive analysis →

Healthstream Inc. (HSTM) is a technology company listed in the US with a market value of about $857M. In the twelve months to September 30, 2026 it had revenue of $328M and net income of $20M, a net margin of 6.2%.

Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (1/5).

Key numbers: a P/E of 40.0, a price to free cash flow of 12.4, 5-year revenue growth of 4% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 47% below the current price.

About Healthstream

Healthstream is listed in the US and classified in computer software: programming data processing, IPO year 2000. Revenue went from $171M in 2014 to $304M in 2025, growth of about 5.4% a year. It was profitable in 10 of the last 10 years in our data. It spends 17% of revenue on research and development.

Score: 2.6 / 5

Value1/5
Future growth1/5
Track record1/5
Financial health5/5
Shareholder returns5/5

Checks passed

  • P/FCF below 20
  • Strong R&D investment or growth above 20%
  • Profitable 5 years in a row
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)40.0
Forward P/E34.5
P/FCF12.4
P/S2.6
P/B2.1
EV/EBITDA10.9
PEG5.92
Dividend yield0.50%
FCF yield8.1%
Shareholder yield4.0%
Intrinsic value vs. price−47%

Growth and quality

Revenue growth (1 yr)4.3%
Revenue growth (5 yrs, per year)4.4%
EPS growth (5 yrs, per year)6.8%
FCF growth (3 yrs, per year)6.5%
Net margin (5-yr avg.)5.0%
ROIC (5-yr avg.)3.4%
Profitable years (of last 10)10
Years paying a dividend7

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$328M$304M$292M$279M$267M$257M$245M$254M$232M$248M$226M
Net income$20M$18M$20M$15M$12M$6M$14M$16M$32M$10M$4M
Free cash flow$69M$60M$56M$62M$49M$39M$34M$44M$36M$41M$19M
EPS (diluted)$0.70$0.61$0.66$0.50$0.39$0.18$0.44$0.49$1.00$0.31$0.12
Net margin6.2%6.0%6.9%5.5%4.5%2.3%5.8%6.2%13.9%4.0%1.7%
ROIC—4.3%4.5%3.6%2.7%1.7%3.4%3.1%3.8%2.7%1.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $36.00, 29% above the current price; targets range from $32.00 to $40.00; the consensus rating is “Hold”; expected EPS is $0.81 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Healthstream’s P/E ratio?

About 40.0, based on the last twelve months of diluted earnings per share (forward P/E about 34.5).

Is Healthstream stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 47% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Healthstream pay a dividend?

Yes. The dividend yield is about 0.50%, and it has paid dividends for 7 years in our data.

Is Healthstream a good stock to buy?

We do not give buy or sell advice. Healthstream scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.